Schizophrenia, published by NATURE PORTFOLIO, is a pioneering open-access journal established in 2022, dedicated to advancing the scientific understanding of schizophrenia and its associated disorders. With its commitment to disseminating high-quality research without barriers, this journal aims to provide a platform for innovative studies, reviews, and meta-analyses that enhance clinical practices and therapeutic approaches. The journal is strategically located in Berlin, Germany, a hub for mental health research and innovation. By facilitating open exchange among researchers, professionals, and students, Schizophrenia aspires to be at the forefront of the global discourse on psychiatric disorders, driving forward critical advancements that can translate into improved patient care and outcomes. With a focus on promoting the latest findings in epidemiology, neurobiology, pharmacology, and psychosocial interventions, this journal is poised to become an essential resource for scholars and practitioners alike, eager to make significant contributions to the field.

HEADACHE is a premier academic journal dedicated to advancing the study of headache disorders through innovative research and clinical insights. Published by WILEY, this influential journal has been serving the neurology community since its inception in 1961 and is recognized as a leader in its field, boasting an impressive Q1 ranking in both Neurology and Neurology (clinical) categories for 2023. With a robust Scopus ranking of #48 in clinical neurology and #26 in neuroscience, HEADACHE consistently publishes high-quality research that contributes to the understanding and treatment of headache disorders worldwide. Although it does not offer open access options, the journal remains accessible to a wide audience through various institutional subscriptions. It aims to provide a platform for researchers, healthcare professionals, and students to exchange ideas and develop new strategies for headache management, making it an essential resource for those dedicated to improving patient outcomes in this challenging area of healthcare.

NEUROMUSCULAR DISORDERS is a premier academic journal published by PERGAMON-ELSEVIER SCIENCE LTD, focusing on the latest research and developments in the fields of neurology, genetics, and pediatric health. With an ISSN of 0960-8966 and an E-ISSN of 1873-2364, this journal has established a significant presence since its inception in 1991, and it continues to contribute to the scientific community with its impactful findings and reviews. The journal boasts a commendable impact factor, reflected in its placement in the Q2 category for Clinical Genetics and Neurology, as well as its positioning in the top tier Q1 for Pediatrics, Perinatology and Child Health according to the latest quartile assessments. With Scopus rankings such as Rank #71/330 in Pediatrics and Rank #51/99 in Clinical Genetics, NEUROMUSCULAR DISORDERS is recognized for its contribution to advancing knowledge in neuromuscular diseases. The journal is essential for researchers, clinicians, and students interested in the intricate relationship between genetics and neurological disorders, providing valuable insights that drive innovation and improve patient care.

Acta Epileptologica is a prominent open-access journal published by SPRINGERNATURE, dedicated to advancing research in the fields of neurology and clinical neurology. With its ISSN 2096-9384 and E-ISSN 2524-4434, this journal has established itself as a key resource for researchers and practitioners worldwide, particularly since its transition to open access in 2019. Based in the United Kingdom, Acta Epileptologica aims to disseminate high-quality research and foster scholarly collaboration, as evidenced by its consistent Q3 ranking in both neurology and clinical neurology categories as of 2023. Although currently positioned in the lower percentiles on Scopus, the journal plays a critical role in exploring emerging trends and novel therapeutic approaches in epilepsy research, making it an essential platform for academics, healthcare professionals, and students deeply invested in the evolving landscape of neurological disorders.

STROKE is a premier academic journal published by Lippincott Williams & Wilkins, dedicated to advancing the fields of neurology, cardiology, and specialized nursing. With an impressive impact factor and consistently ranked in the Q1 category across multiple disciplines—such as Advanced and Specialized Nursing, Cardiology, and Neurology—this journal serves as a crucial platform for researchers and healthcare professionals. It spans a rich historical context from 1970 to 2024, offering invaluable insights into stroke research and related cerebral vascular issues. The journal is committed to disseminating high-quality research that informs clinical practices and guides policy-making in public health. With a focus on empirical studies and clinical trials, STROKE stands as an essential resource for those invested in the complexities of neurological interventions and cardiovascular health. Ensure your access to this influential publication as it shapes the future of medical science and patient care.

ACTA NEUROLOGICA SCANDINAVICA is a prestigious journal published by Wiley that has significantly contributed to the field of neurology and neuroscience since its inception in 1961. With a broad scope encompassing clinical and experimental research, this journal is esteemed for its rigorous peer-review process and high-quality publications. Located in the United Kingdom, it is recognized in the 2023 category quartiles as Q1 in Medicine (miscellaneous) and Q2 in both Neurology and Clinical Neurology, indicating its strong influence and relevance within the medical community. With an H-index demonstrating consistent citation impact, ACTA NEUROLOGICA SCANDINAVICA holds a Scopus rank of #86 out of 400 in Clinical Neurology, reflecting its contribution to advancing current knowledge and practice. Researchers, professionals, and students alike will find in this journal a valuable resource for the latest findings, discussions, and developments in understanding neurological disorders and treatments, furthering educational and clinical endeavors alike.

Epilepsy Currents, published by SAGE Publications Inc, is a vital scholarly journal dedicated to the field of neurology, specifically focusing on epilepsy and seizure-related disorders. With its ISSN 1535-7597 and E-ISSN 1535-7511, the journal aims to disseminate high-quality research, reviews, and clinical insights that contribute to the understanding and management of epilepsy. Boasting a Q3 ranking in clinical neurology for the year 2023, it is positioned among the noteworthy academic resources available to professionals and researchers alike, with its Scopus rank placing it within the 36th percentile of its category. Despite its current non-open access status, the journal remains an essential repository of knowledge for those looking to deepen their expertise in neurology and to stay abreast of the latest developments in the field. Operating out of Thousand Oaks, California, Epilepsy Currents emphasizes evidence-based practices and innovative approaches, encouraging an active dialogue within the academic community and ensuring its ongoing relevance as it converges from 2011 to 2024.

Epilepsia Open is a premier open access journal dedicated to advancing the field of neurology, particularly in the area of epilepsy research and clinical practice. Published by WILEY since 2016, this journal aims to provide a platform for high-quality, peer-reviewed research that fosters collaboration among researchers, clinicians, and educators within the global neurological community. With an impactful presence in the field, it holds a prestigious Q2 ranking in both Neurology and Clinical Neurology categories as of 2023 and has been recognized for its contributions to the understanding of epilepsy through its diverse range of articles, reviews, and clinical studies. Researchers and practitioners can benefit from the journal's open access model, which ensures that valuable findings are readily available to the public, promoting further developments in treatment and care. The journal's significant visibility is reflected in its Scopus rankings, where it ranks in the top half of peer-reviewed journals in both Neurology and Neuroscience categories. For those committed to improving the lives of those affected by epilepsy, Epilepsia Open represents a crucial resource for cutting-edge knowledge and innovative practices.

The Journal of Pediatric Epilepsy, published by GEORG THIEME VERLAG KG, is a dedicated platform for advancing the understanding and treatment of pediatric epilepsy. With ISSN 2146-457X and E-ISSN 2146-4588, this journal provides vital insights and research findings relevant to clinicians, researchers, and students in the fields of neurology, pediatrics, and psychiatry. Although its coverage in Scopus was discontinued from 2012 to 2015, the journal continues to contribute to the body of knowledge within this critical area by focusing on novel therapeutic strategies, clinical studies, and case reports that address the unique challenges faced by children with epilepsy. The journal is committed to fostering collaboration and innovation in the treatment of pediatric seizure disorders, making it an essential resource for anyone dedicated to improving outcomes in this vulnerable population.

Neurodegenerative Diseases, published by KARGER, is a prominent academic journal dedicated to advancing the field of neurology and neuroscience. With an ISSN of 1660-2854 and E-ISSN 1660-2862, this journal serves as a vital platform for researchers, professionals, and students engaged in the exploration of neurodegenerative disorders from various perspectives, including clinical applications and therapeutic interventions. Spanning two decades since its inception in 2004 and set to converge in 2024, it has steadily built a reputation within the academic community, achieving a commendable Q2 ranking in clinical neurology and Q3 in general neurology according to the 2023 category quartiles. The journal boasts an impressive Scopus rank of 114/400 (71st percentile) in clinical neurology and 58/192 (70th percentile) in neuroscience neurology. While not classified as open access, the publication provides critical insights into the latest research and developments, making it an essential resource for anyone dedicated to understanding and combating neurodegenerative diseases.